 | Up a level |
Number of items: 1.
Sehouli, J., Mahner, S., Neunhoeffer, T., Harter, P., de Gregorio, N., Fridrich, C., Markmann, S., Richter, R., Potenberg, J., Lorenz, R., Schmidt, M., Doering, G., Belau, A., Lueck, H. J., Chekerov, R., du Bois, A. and Hilpert, F. (2016). Topotecan (T) +/- Sorafenib (S) for platinum-resistant ovarian cancer (PROC): results of doubleblind placebo-controlled randomized NOGGO - AGO intergroup trial. Int. J. Gynecol. Cancer, 26. S. 2 - 4. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438